A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1035 participants.
Also called NCT07282600
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,035 participants
- Sponsor
- Registry
-
NCT07282600 -
2025-523658-15-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, China, Czechia, Germany, India, Japan, Mexico, Poland, Puerto Rico, Slovakia, South Korea, Spain, Taiwan
- Registry status
- Recruiting
Technical summary
Registry record NCT07282600. Randomized; double masking; primary purpose treatment. Start 2025-12-15 (actual); primary completion 2028-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Acronym
- ENLIGHTEN-2
- Condition
- Overweight
- Condition
- Obesity
- Intervention (Drug)
- Eloralintide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07282600- Content hash
9fa1ac5f785c866f6d9ca200b5eae9c8f9d8f1485066494ac072b9e13644ca00